APLT — Applied Therapeutics Share Price
0.000.00%
Last trade - 00:00- $45.30m
- -$5.46m
- $0.46m
- 20
- 13
- 42
- 13
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.24 | ||
| Price to Tang. Book | 1.24 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 170.32 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -279.21% | ||
| Return on Equity | -83.71% | ||
| Operating Margin | -40875.94% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | 9.99 | 0.46 | 2.3 | 32.75 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the development of drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including classic galactosemia, sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 (PMM2)-congenital disorder glycosylation (CDG). The Company is also developing AT-001, an investigational, ARI developed as an oral therapy for the treatment of diabetic cardiomyopathy (DbCM). It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type II diabetes. The Company’s pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy (DR).
Directors
- Shoshana Shendelman CHM (42)
- Chids Mahadevan CFO
- Adam Hansard OTH (45)
- Riccardo Perfetti OTH (61)
- Teena Lerner LED (63)
- Leslie Funtleyder IND (51)
- Stacy Kanter IND (62)
- Joel Marcus IND (73)
- Jay Skyler IND (74)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- January 20th, 2016
- Public Since
- May 9th, 2019
- No. of Shareholders
- 30
- No. of Employees
- 35
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 141,575,526
- Address
- 545 FIFTH AVENUE, SUITE 1400, NEW YORK, 10017
- Web
- https://www.appliedtherapeutics.com/
- Phone
- +1 2122209226
- Auditors
- Ernst & Young LLP
Upcoming Events for APLT
Q3 2025 Applied Therapeutics Inc Earnings Release
Similar to APLT
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Applied Therapeutics share price?
As of Today at 19:17 UTC, shares in Applied Therapeutics are trading at $0.32. This share price information is delayed by 15 minutes.
How has the Applied Therapeutics share price performed this year?
Shares in Applied Therapeutics last closed at $0.32 and the price had moved by -92.69% over the past 365 days. In terms of relative price strength the Applied Therapeutics share price has underperformed the S&P500 Index by -93.47% over the past year.
What are the analyst and broker recommendations for Applied Therapeutics?
The overall consensus recommendation for Applied Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Applied Therapeutics dividend yield?
Applied Therapeutics does not currently pay a dividend.
Does Applied Therapeutics pay a dividend?
Applied Therapeutics does not currently pay a dividend.
When does Applied Therapeutics next pay dividends?
Applied Therapeutics does not currently pay a dividend.
How do I buy Applied Therapeutics shares?
To buy shares in Applied Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Applied Therapeutics?
As of the previous close price of $0.32, shares in Applied Therapeutics had a market capitalisation of $45.30m.
Where are Applied Therapeutics shares listed?
Here are the trading details for Applied Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: APLT
What kind of share is Applied Therapeutics?
Based on an overall assessment of its quality, value and momentum Applied Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Applied Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Applied Therapeutics is $2.88. That is 800% above the last closing price of $0.32.
Analysts covering Applied Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.55 for the next financial year.
Find out moreWhat is the trend in the Applied Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Applied Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -67.46%.
As of the last closing price of $0.32, shares in Applied Therapeutics were trading -88.23% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Applied Therapeutics PE Ratio?
The Applied Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.32.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Applied Therapeutics?
Applied Therapeutics' management team is headed by:
- Shoshana Shendelman - CHM
- Chids Mahadevan - CFO
- Adam Hansard - OTH
- Riccardo Perfetti - OTH
- Teena Lerner - LED
- Leslie Funtleyder - IND
- Stacy Kanter - IND
- Joel Marcus - IND
- Jay Skyler - IND